Log In

INVEST IN EO2 CONCEPTS TODAY!

Oxygen-Enhanced Technology for Advanced Wound Healing and Skin Support

EO2 Concepts is an advanced wound healing technology company leveraging continuous diffusion of oxygen (CDO) therapy to commercialize innovative medical modalities. The company’s primary in-market product is OxyGeni, a wearable device designed to heal wounds to complete closure while simultaneously supporting skin and soft tissue restoration, shortening recovery time, reducing pain, and minimizing the formation of scar tissue in the process.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$702,149.90 Raised

REASONS TO INVEST

EO2’s CDO therapy system is an enhanced wound care solution that improves patient outcomes when recovering from chronic wounds, skin injuries, or surgeries. It utilizes the continuous delivery of oxygen directly to the tissue, which has been shown to achieve faster healing, reduced pain levels, and overall improved skin health.*

EO2’s addressable market encompasses two multibillion dollar divisions. Globally, the chronic wound care sector is estimated to be worth over $20B,*while the aesthetics and cosmetic surgery industry is valued at $63.4B and expected to exhibit nearly double digit CAGR between now and 2030.*

As an industry innovator, EO2 is focused on continual product testing, research, development, and design, in collaboration with key opinion leaders and medical professionals. Our unique position in an expanding marketplace is secure through 2038, protected by numerous national and international patents, as well as additional patents pending.

*Market information provided by (source) (source) (source)

overview


Advanced Wound Care Therapy Powered By Pure Oxygen

For patients recovering from wounds (i.e. ulcers and burns), amputations, and cosmetic/restorative surgeries, oxygen is one of the most vital elements in the wound-healing process (source). Understanding this, EO2 has developed proprietary technology that allows pure, humidified oxygen to be continuously diffused directly into the tissue, thereby creating an optimal environment for skin repair and restoration. The OxyGeni is an all-inclusive system that offers oxygen generation, wound monitoring, oxygen diffusion dressings, and accessories, all in one lightweight and discrete wearable device.


The Problem & Our Solution



Making CDO Therapy Accessible To Support Wound Healing 24/7



A common obstacle to proper healing of wounds is a lack of oxygen, caused by blocked or damaged blood pathways. Oxygen via the bloodstream is what provides nourishment to the skin and dermal tissues, fueling important processes like collagen formation, cellular regeneration, antibacterial activity, and repair. When the body doesn’t have access to sufficient levels of oxygen, it becomes much harder to carry out these essential functions. However, most existing wound care options involve covering damaged skin, thereby blocking direct flow of oxygen to the tissue.


source

As a solution, EO2 has developed a system that not only restores oxygen levels, yet also enhances those levels beyond the body’s normal capacity. Using our wearable device, patients receive advanced wound care anywhere, anytime, and are able to accelerate the entire healing process. Additionally, because CDO therapy has benefits for reducing pain and inhibiting the formation of scars, the technology helps to restore quality of life. Positive outcomes from treatment with OxyGeni range from improving aesthetic appearance to preventing amputation.  

The Market & Our Traction



Building a Science-Backed Brand That’s Responsive To An Evolving Market 


Over the last several years, EO2 has been making significant progress across many verticals. In clinical trials, the company’s technology has been substantiated by multiple studies, with peer-reviewed papers published by notable national and international industry leaders. Meanwhile, on the marketing side, we’ve seen mass social media response to the performance of our products for patients, especially in the cosmetic procedures market. 



As a result of our success in these areas, EO2 has seen a robust increase in sales. Within the plastics and aesthetics market, we’ve demonstrated triple-digit YOY growth and in Canada, the company has moved from unpaid trials to payment models in six provinces. By creating products designed to accommodate today’s telehealth models, we are enabling patients to be more involved in their own care through mobile app design, automated product delivery, and AI-driven communication. 



Although EO2 Concepts initially developed solutions for the chronic wound care market, the company has exciting opportunities to expand into other markets based on the science of oxygen therapy’s efficacy and the feedback of medical users. Our newest and fastest-growing market is in aesthetic and reconstructive surgery, as the technology can be used to facilitate healing following face lifts, breast reductions, laser facials, and cosmetic injectables. 


Why Invest



Invest in Proven Technology That Helps People Heal



Chronic wounds affect millions of patients each year and the costs to our healthcare system for diabetic foot complications alone are comparable to all cancers combined (source). Complications from a wound can last months or years, sometimes resulting in amputations, and severely impacting quality of life for patients. Having developed a system that can improve recovery outcomes, in a more accessible and affordable format, EO2’s vision is to bring our technology to the medical community and become the standard of care across multiple segments. Be a part of our success story by investing on Start Engine!



ABOUT

HEADQUARTERS
12500 Network Blvd Ste 310
San Antonio, TX 78249

EO2 Concepts is an advanced wound healing technology company leveraging continuous diffusion of oxygen (CDO) therapy to commercialize innovative medical modalities. The company’s primary in-market product is OxyGeni, a wearable device designed to heal wounds to complete closure while simultaneously supporting skin and soft tissue restoration, shortening recovery time, reducing pain, and minimizing the formation of scar tissue in the process.

TEAM

Mark Niederauer

Mark Niederauer

President, CEO, Board Member

Dr. Niederauer has served as the Company’s Chief Technology Advisor since June of 2008, has served as the Chief Technology and Operating Officer since January of 2010 and became the President and CEO in August of 2021. He has more than 25 years of experience in commercialization, engineering, product development and manufacturing of pharmaceuticals medical devices, including regulatory and quality compliance. Dr. Niederauer has worked for Bayer Chemikalien in Leverkusen, Germany, Hoechst Celanese in Corpus Christi, TX, and for OsteoBiologics, Inc. (OBI) in San Antonio, TX, which was the acquired by Smith & Nephew Endoscopy. Dr. Niederauer earned a PhD in Biochemical Engineering, with a focus in Genetics, from Iowa State University. He is also a Fulbright Scholar, earning the equivalent of a Master of Science degree from environmental engineering work at the Universität Stuttgart in Germany. Dr. Niederauer has co-authored numerous articles and presentations and is a co-inventor on multiple patents.

Ken Melani, MD

Ken Melani, MD

Board member

Dr. Melani is currently the owner of KRM Group LLC, a healthcare consulting firm, and managing director of Velocity Fund Partners LLC, a life sciences venture capital fund. He started his career as a practicing Internist where he founded and later became Chairman and CEO of a physician-hospital organization called West Penn Cares. Over the next twenty-five years he served in a variety of executive leadership roles at Highmark Inc, culminating as the President and CEO from 2003-2012. He was credited with growing Highmark into one of the leading healthcare companies in the United States and personally regarded as one of the top healthcare executives in the country. Dr. Melani received his BA from Washington and Jefferson College, where he graduated Summa Cum Laude, and went on to receive a Doctorate of Medicine from The Wake Forest University School of Medicine.

Dave Kazynski

Dave Kazynski

Exec. VP of Sales and Marketing, Board Member

Mr. Kazynski is the President of VGM’s HOMELINK business which is a insurance network contractor for a wide range of various healthcare services for members of VGM’s independent Durable Medical Equipment suppliers. HOMELINK has about 110 different managed care contracts. He served many years as a CFO and COO to a number of proprietary hospitals in IA and MO including a hospital sold to Tenet. Mr. Kazynski has been a member on the Center for Medicare Services DME Program Advisory and Oversight Committee (PAOC) and functioned as the hospital liaison for local Managed Care Plans. Mr. Kazynski graduated from the University of Northern Iowa in 1979 with a B.A. in Psychology, and then earned an M.B.A. in Finance in 1981.

Peter Smith

Peter Smith

Chairman of the Board of Directors

Mr Smith served as the Chief Operating Officer of Baxter's Japanese Subsidiary located in Tokyo and later was the President of Baxter's Caremark Division. He founded and led CorSolutions, a disease management company. Subsequently, he also founded and led Medmark, a specialty pharmaceutical distribution business. He currently sits on the Board of four other privately held healthcare companies. Mr Smith received his AB from Princeton University and his MBA from the University of Chicago.

Jim DeYoung

Jim DeYoung

Board Member

Mr. DeYoung is founder and a principal of Winston Partners Incorporated, which provides strategic corporate advisory and investor relations services to private and public companies. In addition, Mr. DeYoung is a member of the management of DW Investments, LLC. Mr. DeYoung formerly was a general partner of Resource Ventures L.P. He was responsible for several of the fund’s investments. He served at Baxter International, Inc. in marketing, investor relations, public relations and corporate financial management functions. He is a Trustee of Rush University Medical Center and serves on the Executive, Investment and Information Technology Committees of the Board. Mr. De Young serves on a number of boards in the Chicago area. Mr. DeYoung is a graduate of Washington and Lee University (B.A.) and received his J.D. degree from Northwestern University School of Law.

Justin Cypert

Justin Cypert

Controller

Mr. Cypert served as the company’s Business Manager since 2009 and became the companies Controller in 2014. He has overall responsibility for business financial operations including treasury, budgeting, forecasting and accounting management. Mr. Cypert has over 20 years of experience in a range of professional areas including manufacturing, business process, financial reporting, audit and compliance. Mr. Cypert has worked for Philips Semiconductors, OsteoBiologics and Smith & Nephew Endoscopy. Mr. Cypert earned his Bachelors in Finance from the University of Texas at San Antonio.

James P. Daley

James P. Daley

Director of Operations

Mr. Daley has over 45 years’ experience in electrical and mechanical engineering, manufacturing and product development in the fields of medical devices and aerospace. He oversees the research, design, manufacturing, packaging and testing of products. Mr. Daley also manages all plant operations, including shipping & receiving and facility maintenance. Mr. Daley is a co-inventor on multiple patents.

Cyndi Gilliam, BSN, RN, FACCWS

Cyndi Gilliam, BSN, RN, FACCWS

Director of Clinical Affairs

Mrs. Gilliam is the Director of Clinical Affairs for EO2. She has worked as an industry Clinical Specialist for the last 10 years, including experience at Kinetic Concepts Inc. Her experience and expertise as a wound care RN has been instrumental in the relationships and educational programs she has built throughout the years. She has excellent contacts across the country within wound care, colorectal surgery, orthopedic, and other specialties. Her passion is integrating her business knowledge with her clinical knowledge to achieve the greatest outcomes for both her patients and clinicians, while achieving success for the company. She is excited to bring her knowledge and skills to help bring EO2 to the forefront of wound care as a standard of care therapy system.

Kate Biasiolli

Kate Biasiolli

Marketing Manager

Mrs. Biasiolli currently holds position as both regional account manager in Texas as well as marketing manager. She has vast experience with in the wound care industry spanning over 15 years. During her tenure at the largest negative pressure wound therapy company, Kinetic Concepts Inc, Mrs. Biasiolli planned, developed and executed customer training throughout the globe while managing her team and million dollar budget. Her honors degree in biology combined with a certificate in adult education provides her a strong background to grasp complex processes and simplify into easy to understand, relatable concepts.

Joseph Monosmith

Joseph Monosmith

Quality Assurance Manager

Mr. Monosmith is the Quality Assurance Manager for EO2, with 13 years of experience in the Medical Device field. He has experience in manufacturing, assembly, shipping/receiving, quality control and quality assurance. In the medical device space, he previously worked in manufacturing and quality for the Endoscopy Division of Smith & Nephew. He is dedicated to, and strongly believes in, the innovation that EO2 brings to wound care, as well as, the positive impact to the quality of life for the patient population.

TERMS

EO2 Concepts
Overview
PRICE PER SHARE
$1.59
DEADLINE
Jun 30, 2023
VALUATION
$78.44M
FUNDING GOAL
$15k - $1.23M
Breakdown
MIN INVESTMENT
$298.92
MAX INVESTMENT
$1,234,997.52
MIN NUMBER OF SHARES OFFERED
9,433
MAX NUMBER OF SHARES OFFERED
776,728
OFFERING TYPE
Equity
ASSET TYPE
Preferred Stock
SHARES OFFERED
Series A Preferred Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets

$3,568,756

$1,719,463

Cash & Cash Equivalents

$606,116

$72,823

Accounts Receivable

$1,006,778

$1,024,322

Short-Term Debt

$2,090,703

$1,386,548

Long-Term Debt

$7,799,257

$4,446,595

Revenue & Sales

$2,983,348

$1,544,623

Costs of Goods Sold

$884,839

$640,373

Taxes Paid

$0

$0

Net Income

-$2,738,366

-$2,517,980

*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Time Based Perks

o First 72 hours – 10% Super Early Bird Bonus

o First week (days 4-7) – 8% Very Early Bird Bonus

o First 3 weeks (week 2 & 3) - 5% Early Bird Bonus

Amount Based Perks

o $600+ – 3% bonus shares , Member, Contributing to enabling advanced healing with oxygen.

o $1,500+ – 5% bonus shares, Leader, Leading the way in oxygen healing solutions.

o $5,000+ – 8% bonus shares, Innovator, Bringing next generation solutions to oxygen delivery and patient monitoring.

o $15,000+ – 10% bonus shares, Visionary, Ensuring the long-term growth and innovation in oxygen solutions for health care. 

Loyalty Bonus - 10% Bonus Shares for Friends and Family 

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Electrochemical Oxygen Concepts, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series A Non-Voting Preferred Stock at $1.59/ share, you will receive 110 shares of Series A Non-Voting Preferred Stock, meaning you'll own 110 shares for $159. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and an the Loyalty bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company will not incur irregular use of proceeds.

PRESS

Article Image
Meta-analysis Published

Efficacy of Topical Wound Oxygen Therapy in Healing Chronic Diabetic Foot Ulcers: Systematic Review and Meta-Analysis

Article Image
Fully Blinded Placebo Study

Continuous diffusion of oxygen improves diabetic foot ulcer healing when compared with a placebo control: a randomised, double-blind, multicentre study

Article Image
VIDEO: EO2 on PBS SciTech Now

Featured on PBS SciTech Now on July 14th, 2017, Dr. Mark Niederauer, explains the EO2 Device and CDO Therapy.

ALL UPDATES

06.06.23

NEW Registered Trademark for CDO in the UK!

EO2 is pleased to announce issuance of a certificate of registration for the United Kingdom Trademark to add to their robust portfolio. The UK recently issued patent No. UK00003881009, in International Class 10, covering “Medical devices, namely, portable low-dose tissue oxygenation units for promoting wound healing, sold as unit with medical tubing and parts and accessories thereof.” CDO will now be under trademark protection until 2033.

Click the link to learn more and join us! - https://investment.startengine.com/eo2

06.05.23

EO2 Welcomes New CFO!

EO2 is excited to welcome Anthony (Tony) Gallardo to the team as the new Chief Financial Officer. After earning his Bachelors degree in accounting from the University of Texas at San Antonio, Tony has been a Certified Public Accountant with over 30 years of financial and operational experience. Tony has worked as COO and CFO for entrepreneurial companies in home health care and mental health. With over 30 years of experience Tony is adept at improving processes, including financial reporting, cash flow, internal controls and compliance with contract and regulatory requirements. 

As a financial leader Tony has extensive experience with budgeting and forecasting. He has guided operational teams to successfully prepare and exceed budgets. Additionally, over his career he has successfully guided the accounting team to set up the internal controls and processes for high growth companies.

We are excited for this new addition to our EO2 team and looking forward to good things to come.

Click the link to learn more and join us! - https://investment.startengine.com/eo2

06.02.23

Join us in Redefining the Speed & Comfort of Wound Care

Our next stage of growth includes expanding our sales and inventory to reach new markets and developing our smart phone apps to connect to the cloud, allowing patients to track their healing process, similar to a Fitbit. Also allowing doctors and nurses to remotely interact with their patients. Join us in redefining the speed and comfort of wound care.


Click the link to learn more and join us! - https://www.startengine.com/offering/eo2

05.19.23

NEW Revolutionary Dressing Design for Cosmetic Surgery!

We are proud to announce the launch of our latest product, a revolutionary dressing design within our CDO portfolio. We are rapidly making a mark within the $63 billion plastics and cosmetic surgery industry, seeing explosive growth thanks to our focus on meeting the needs of early adopters. Our dedicated engineering team has worked closely with top thought leaders in this field to develop a dressing design that seamlessly integrates into their practices. The 2x10 dressing design has been specifically created to provide the necessary oxygen to decrease pain levels and accelerate the healing process for incision lines resulting from procedures such as tummy tucks and breast augmentations. We invite you to join us on our journey towards innovation and success within this exciting industry.

Click the link to learn more and join us! - https://www.startengine.com/offering/eo2

05.16.23

$63.4B Aesthetics Industry Expected to Exhibit Nearly Double Digit CAGR by 2030!

EO2’s addressable market encompasses two multibillion dollar divisions. One of those is the aesthetics and cosmetic surgery industry is valued at $63.4B and expected to exhibit nearly double digit CAGR between now and 2030. Join us in expanding our influence in this rapidly growing market. 

Click the link to learn more and join us! - https://www.startengine.com/offering/eo2

05.10.23

600K Fundraising Milestone Reached!

Another fundraising milestone met this week! 

We have now passed $600k and are approaching $650k. If you haven’t had a chance, please take a moment to check out our investment opportunity on StartEngine.

Click on the link to learn more and join us! - https://www.startengine.com/offering/eo2

05.05.23

EO2 Welcomes New Board Member

We are pleased to welcome our newest board member Ken Melani, MD!

Dr. Melani is currently the owner of KRM Group LLC, a healthcare consulting firm, and managing director of Velocity Fund Partners LLC, a life sciences venture capital fund. He started his career as a practicing Internist where he founded and later became Chairman and CEO of a physician-hospital organization called West Penn Cares. Over the next twenty-five years he served in a variety of executive leadership roles at Highmark Inc, culminating as the President and CEO. He is credited with growing Highmark into one of the leading healthcare companies in the United States and is personally regarded as one of the top healthcare executives in the country. Dr. Melani received his BA from Washington and Jefferson College, where he graduated Summa Cum Laude, and went on to receive a Doctorate of Medicine from The Wake Forest University School of Medicine.

Interested in learning more about our team? Click the link below to learn more and join us! - https://www.startengine.com/offering/eo2

05.02.23

EO2: A Breath of Fresh Air in the World of Wound Care

Are you tired of hearing the same old puns in the medical industry? Then get ready for a breath of fresh air with EO2. With its CDO therapy system, EO2 is revolutionizing wound care with the power of oxygen. But it's not just about the puns - EO2 is serious about promoting faster healing, reducing pain levels, and improving overall skin health. And with a commitment to continual product testing, research, development, and design, EO2 is always looking for ways to stay ahead of the game. So whether you're a medical professional or just a fan of a good pun, check out EO2 and discover the power of oxygen in wound care.


Click on the link to learn more and join us! - https://www.startengine.com/offering/eo2

04.28.23

Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the EO2 Concepts offering. Here's an excerpt describing the specifics of the change:


EO2 Concepts extending their campaign end date and updated their financials


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

04.24.23

EO2 Announces New Patent

EO2 is pleased to announce the issuance of another patent to add to their robust patent portfolio. Canada recently issued patent number 3005473 for EO2’s proprietary and novel CDO System for enhancing tissue oxygenation using smart sensors to detect conditions in the wound bed.  This allows for real-time control and monitoring of patient care in a remote setting.

Learn more and join us at: https://www.startengine.com/offering/eo2

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into EO2 Concepts.

$298

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$600

Member

Invest $600+ and receive 3% Bonus shares

$1,500

Leader

Invest $1,500+ and receive 5% Bonus shares

$5,000

Innovator

Invest $5,000+ and receive 8% Bonus shares

$15,000

Visionary

Invest $15,000+ and receive 10% Bonus Shares

JOIN THE DISCUSSION

0/2500

WC
W Kim Colich

87 INVESTMENTS

6 days ago

Hi Mark, I'm wondering... Do you see potential for your product in the world of sports, i.e. helping athletes perform their absolute best with boosts of oxygen to their tissues? Thanks. Blessings

1

0













CL
Christopher Lill

17 INVESTMENTS

10 days ago

Hello, I would like to know more about your patents ie how many you have and how many pending? Th×

2

0













SH
Stephen Hart

10 INVESTMENTS

a month ago

Is this system available now?

4

0













TD
Terry Dew

2 months ago

What differentiates you from other similar units on the market?

1

0













MM
Michael Myers

2 months ago

Exciting technology, I work in the DME industry and have dealt w/NPWT which is a pain both for the patient and the DME, would be interested in considering this as a new product line, especially w/cash options to plastic/reconstructive surgery being a potential customer.

1

0













JR
Joseph Russo

2 months ago

This really interested me. As my mother in law had her feet slowly taken off but by bit because she could not heal the area. This would have save her life because she would not have suken into a deep depression that she never came out of. I believe this will save more then time and money in medical costs but the mental health issues related to wounds that don’t heal.

1

0













RJ
Ronnie Jaikaran

3 months ago

Hello. Is there any tax documents that I need from you for my 2022 filing? Start-up investing is all new to me.

1

0













AD
Addison Delk

1 INVESTMENTS

6 months ago

What is your current revenue? How did you get to a $78m valuation?

1

0













RS
Russell Smith

9 INVESTMENTS

7 months ago

Exciting stuff for sure - i wonder if you can further detail where you are in the revenue and expansion cycle ? - you mentioned moving from free to paid in 6 Canadian provinces, but what is happening in the US and other areas ? what state are the finances in currently and what would next steps and use-of-funds be used-for please ? sorry for the questions, but interested in the tech....thanks

1

1













HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$702,149.90
INVESTORS
216
MIN INVEST
$298.92
VALUATION
$78.44M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.